Evotec Shares Hit 52-Week Low After Major Guidance Revision, All Eyes on August Report

Evotec's stock tumbles 30% after slashing 2026 outlook; half-year results on Aug 13 will test whether setback is temporary or signals deeper business issues.

The Hamburg-based drug discovery and development partner Evotec faces a pivotal moment on August 13, when its half-year results will either confirm that a recent plunge was a temporary setback or expose deeper cracks in its business model. The stock tumbled nearly 30% in seven days after management slashed its 2026 outlook, leaving the market grappling with a stark divergence between the company’s explanation and analyst skepticism.

On July 13, Evotec issued preliminary second-quarter figures that sent shockwaves through the stock. Revenue guidance for the full year was cut to a range of €570–€610 million, well shy of the original €700–€780 million target. The EBITDA forecast went from breakeven-to-positive (up to €40 million) to a loss of between €70 million and €105 million. The stock responded by hitting a fresh 52-week low of €3.19, though it has since nudged up to around €3.49 — still 55% below its year-high of €7.75.

Management attributed the shortfall to timing rather than structural deterioration. CFO Claire Hinshelwood outlined three drivers: roughly 40% of the revenue gap came from milestone payments pushed into 2027, another 45% stemmed from weaker contributions from new strategic partnerships, and the remaining 15% reflected lower revenue recognition in existing contracts. The core message was that the revenue would arrive eventually, just later than expected.

Analysts offered a more cautious interpretation. RBC’s Charles Weston called the revision “another substantial profit warning,” while TD Cowen downgraded Evotec from Buy to Hold, slashing its price target from $4 to $2 (or €7 to €4). The broker’s note highlighted that operating numbers already show strain: second-quarter total revenue fell 16% to roughly €144 million, with the core Discovery & Preclinical Development segment dropping 15% to €108 million and the Just-Evotec Biologics unit declining 17% to €35 million. Because partnership revenues carry higher margins, Hinshelwood warned that their absence hits the bottom line disproportionately — a sign of structural margin pressure that goes beyond mere schedule shifts.

Oversold Conditions Meet a Cost-Cutting Drive

Despite the gloom, technical indicators flash a potential for a near-term bounce. The relative strength index sits at 22.6, deep in oversold territory that historically precedes short-lived rallies. The stock is trading 35–36% below its 200-day moving average, confirming the bearish medium-term trend but also opening the door to mean-reversion plays for nimble traders.

Evotec’s management points to several levers that could stabilize the situation. The base business — specifically Discovery & Preclinical Development excluding strategic partners — posted 28% year-on-year revenue growth, evidence that the underlying drug-discovery engine remains active. The company also highlighted its “Horizon” cost-saving program, which aims to deliver €75 million in annual efficiencies by the end of 2027, with between one-fifth and one-third of that already targeted for 2026 through automation, AI, and a shift toward higher-value services.

The August 13 Verdict

All attention now centers on the full half-year report due August 13. If the breakdown of missed partnership contributions proves accurate and the base business continues to accelerate, the stock may stabilize in the €3.40–€3.60 range, potentially re-testing the 50-day moving average near €4.79. A failure to hold €3.19, however, would open the door to multi-year lows. Similarly, any sign of a worsening cash burn rate or pipeline weakness in the August release could trigger another wave of selling.

For now, Evotec’s narrative hinges on whether its three-part explanation for the guidance cut holds up — or whether the market’s growing suspicion of a deeper structural malaise proves justified.